| Id: | acc1139 |
| Group: | 2sens |
| Protein: | c-Met |
| Gene Symbol: | MET |
| Protein Id: | P08581 |
| Protein Name: | MET_HUMAN |
| PTM: | phosphorylation |
| Site: | Tyr1349 |
| Site Sequence: | IFSTFIGEHYVHVNATYVNVK |
| Disease Category: | Cancer |
| Disease: | Hepatocellular Carcinoma |
| Disease Subtype: | |
| Disease Cellline: | Hep3B |
| Disease Info: | |
| Drug: | vitamin K1 + sorafenib |
| Drug Info: | "Sorafenib is an oral multikinase inhibitor developed by Bayer Pharmaceuticals, approved by the FDA in 2005, and used for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma, and radioactive iodine-refractory differentiated thyroid cancer. Vitamin K1: - " |
| Effect: | modulate |
| Effect Info: | "The combined use of vitamin K1 and sorafenib enhances the phosphorylation of c-Raf at Ser-43 and Ser-259 sites. It also promotes the phosphorylation of c-Met at Tyr-1349 site, enhancing the inhibitory effect on tumor cell growth." |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 21734462 |
| Sentence Index: | 21734462_9-10 |
| Sentence: | "Both PI3K inhibitor Ly294002 as well as dominate negative Akt plasmid transfection antagonized vitamin K1 plus sorafenib actions on c-Raf phosphorylation and cell growth inhibition, suggesting that c-Met-PI3K-Akt signaling pathway mediated inhibitory c-Raf phosphorylation may play a central role in vitamin K1 plus sorafenib synergy in inhibiting HCC cell growth." |
Sequence & Structure:
MKAPAVLAPGILVLLFTLVQRSNGECKEALAKSEMNVNMKYQLPNFTAETPIQNVILHEHHIFLGATNYIYVLNEEDLQKVAEYKTGPVLEHPDCFPCQDCSSKANLSGGVWKDNINMALVVDTYYDDQLISCGSVNRGTCQRHVFPHNHTADIQSEVHCIFSPQIEEPSQCPDCVVSALGAKVLSSVKDRFINFFVGNTINSSYFPDHPLHSISVRRLKETKDGFMFLTDQSYIDVLPEFRDSYPIKYVHAFESNNFIYFLTVQRETLDAQTFHTRIIRFCSINSGLHSYMEMPLECILTEKRKKRSTKKEVFNILQAAYVSKPGAQLARQIGASLNDDILFGVFAQSKPDSAEPMDRSAMCAFPIKYVNDFFNKIVNKNNVRCLQHFYGPNHEHCFNRTLLRNSSGCEARRDEYRTEFTTALQRVDLFMGQFSEVLLTSISTFIKGDLTIANLGTSEGRFMQVVVSRSGPSTPHVNFLLDSHPVSPEVIVEHTLNQNGYTLVITGKKITKIPLNGLGCRHFQSCSQCLSAPPFVQCGWCHDKCVRSEECLSGTWTQQICLPAIYKVFPNSAPLEGGTRLTICGWDFGFRRNNKFDLKKTRVLLGNESCTLTLSESTMNTLKCTVGPAMNKHFNMSIIISNGHGTTQYSTFSYVDPVITSISPKYGPMAGGTLLTLTGNYLNSGNSRHISIGGKTCTLKSVSNSILECYTPAQTISTEFAVKLKIDLANRETSIFSYREDPIVYEIHPTKSFISGGSTITGVGKNLNSVSVPRMVINVHEAGRNFTVACQHRSNSEIICCTTPSLQQLNLQLPLKTKAFFMLDGILSKYFDLIYVHNPVFKPFEKPVMISMGNENVLEIKGNDIDPEAVKGEVLKVGNKSCENIHLHSEAVLCTVPNDLLKLNSELNIEWKQAISSTVLGKVIVQPDQNFTGLIAGVVSISTALLLLLGFFLWLKKRKQIKDLGSELVRYDARVHTPHLDRLVSARSVSPTTEMVSNESVDYRATFPEDQFPNSSQNGSCRQVQYPLTDMSPILTSGDSDISSPLLQNTVHIDLSALNPELVQAVQHVVIGPSSLIVHFNEVIGRGHFGCVYHGTLLDNDGKKIHCAVKSLNRITDIGEVSQFLTEGIIMKDFSHPNVLSLLGICLRSEGSPLVVLPYMKHGDLRNFIRNETHNPTVKDLIGFGLQVAKGMKYLASKKFVHRDLAARNCMLDEKFTVKVADFGLARDMYDKEYYSVHNKTGAKLPVKWMALESLQTQKFTTKSDVWSFGVLLWELMTRGAPPYPDVNTFDITVYLLQGRRLLQPEYCPDPLYEVMLKCWHPKAEMRPSFSELVSRISAIFSTFIGEHYVHVNATYVNVKCVAPYPSLLSSEDNADDEVDTRPASFWETS
Select PDB:
| Target | Drug name | MOA | Phase | Status | Disease | Source |
|---|---|---|---|---|---|---|
| MET | CABOZANTINIB S-MALATE | Hepatocyte growth factor receptor inhibitor | 4 | - | hepatocellular carcinoma | EMA |
| MET | CRIZOTINIB | Hepatocyte growth factor receptor inhibitor | 4 | - | diffuse large B-cell lymphoma | DailyMed |
| MET | CABOZANTINIB | Hepatocyte growth factor receptor inhibitor | 4 | - | neoplasm | ATC |
| MET | AMIVANTAMAB | Hepatocyte growth factor receptor inhibitor | 4 | - | neoplasm | ATC |
| MET | CAPMATINIB | Hepatocyte growth factor receptor inhibitor | 4 | - | neoplasm | ATC |
| MET | TEPOTINIB | Hepatocyte growth factor receptor inhibitor | 4 | - | neoplasm | ATC |
| MET | CRIZOTINIB | Hepatocyte growth factor receptor inhibitor | 4 | - | neoplasm | ATC |
| MET | CABOZANTINIB S-MALATE | Hepatocyte growth factor receptor inhibitor | 4 | - | renal cell carcinoma | EMA DailyMed |
| MET | CABOZANTINIB S-MALATE | Hepatocyte growth factor receptor inhibitor | 4 | - | thyroid carcinoma | DailyMed |
| MET | CAPMATINIB HYDROCHLORIDE | Hepatocyte growth factor receptor inhibitor | 4 | - | non-small cell lung carcinoma | EMA FDA DailyMed |
| MET | CRIZOTINIB | Hepatocyte growth factor receptor inhibitor | 4 | - | non-small cell lung carcinoma | EMA DailyMed |
| MET | CRIZOTINIB | Hepatocyte growth factor receptor inhibitor | 4 | Terminated | non-small cell lung carcinoma | ClinicalTrials |
| MET | CRIZOTINIB | Hepatocyte growth factor receptor inhibitor | 4 | Active, not recruiting | non-small cell lung carcinoma | ClinicalTrials |
| MET | AMIVANTAMAB | Hepatocyte growth factor receptor inhibitor | 4 | - | non-small cell lung carcinoma | EMA FDA |
| MET | TEPOTINIB HYDROCHLORIDE | Hepatocyte growth factor receptor inhibitor | 4 | - | non-small cell lung carcinoma | EMA FDA DailyMed |
| MET | TIVANTINIB | Hepatocyte growth factor receptor inhibitor | 3 | Completed | hepatocellular carcinoma | ClinicalTrials |
| MET | CABOZANTINIB | Hepatocyte growth factor receptor inhibitor | 3 | Active, not recruiting | hepatocellular carcinoma | ClinicalTrials |
| MET | CABOZANTINIB | Hepatocyte growth factor receptor inhibitor | 3 | Completed | hepatocellular carcinoma | ClinicalTrials |
| MET | CRIZOTINIB | Hepatocyte growth factor receptor inhibitor | 3 | Completed | carcinoma | ClinicalTrials |
| MET | CRIZOTINIB | Hepatocyte growth factor receptor inhibitor | 3 | Recruiting | lung adenocarcinoma | ClinicalTrials |
| MET | CRIZOTINIB | Hepatocyte growth factor receptor inhibitor | 3 | Recruiting | neoplasm | ClinicalTrials |
| MET | ONARTUZUMAB | Hepatocyte growth factor receptor antagonist | 3 | Completed | neoplasm | ClinicalTrials |
| MET | CABOZANTINIB | Hepatocyte growth factor receptor inhibitor | 3 | Active, not recruiting | renal cell carcinoma | ClinicalTrials ClinicalTrials ClinicalTrials ClinicalTrials |
| MET | CABOZANTINIB | Hepatocyte growth factor receptor inhibitor | 3 | Terminated | renal cell carcinoma | ClinicalTrials |
| MET | SAVOLITINIB | Hepatocyte growth factor receptor inhibitor | 3 | Active, not recruiting | renal cell carcinoma | ClinicalTrials |
Note: Only show clinically investigational or approved drugs with protein targets.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACNo intensity data of this site,
show all other sites!
| MET-Ser1000 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -0.707 | ||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | 0.707 | ||||
| PDAC | |||||
| UCEC | |||||
| MET-Ser1016 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.707 | ||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | -0.707 | ||||
| MET-Ser1020 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.152 | ||||
| HGSC | |||||
| ccRCC | |||||
| GBM | -1.442 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | 0.826 | ||||
| PDAC | |||||
| UCEC | 0.464 | ||||
| MET-Ser966 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -1.386 | ||||
| GBM | |||||
| HNSC | |||||
| LUAD | 0.137 | ||||
| LUSC | 1.277 | ||||
| non_ccRCC | -0.477 | ||||
| PDAC | |||||
| UCEC | 0.449 | ||||
| MET-Ser988 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -0.564 | ||||
| GBM | 1.155 | ||||
| HNSC | |||||
| LUAD | -0.59 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MET-Ser990 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.465 | ||||
| HGSC | |||||
| ccRCC | 1.03 | ||||
| GBM | 0.869 | ||||
| HNSC | |||||
| LUAD | -0.033 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | -1.402 | ||||
| MET-Thr977 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.072 | ||||
| HGSC | 2.004 | ||||
| ccRCC | -0.437 | ||||
| GBM | -1.729 | ||||
| HNSC | |||||
| LUAD | 0.108 | ||||
| LUSC | 0.363 | ||||
| non_ccRCC | -0.729 | ||||
| PDAC | 0.221 | ||||
| UCEC | 0.271 | ||||
| METAP2-Ser49 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.344 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.141 | ||||
| GBM | -1.576 | ||||
| HNSC | 0.748 | ||||
| LUAD | 1.077 | ||||
| LUSC | -0.171 | ||||
| non_ccRCC | -1.523 | ||||
| PDAC | 1.13 | ||||
| UCEC | -0.171 | ||||
| METAP2-Ser60 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.054 | ||||
| HGSC | |||||
| ccRCC | 0.85 | ||||
| GBM | -2.125 | ||||
| HNSC | 0.594 | ||||
| LUAD | 0.509 | ||||
| LUSC | 0.165 | ||||
| non_ccRCC | -0.771 | ||||
| PDAC | |||||
| UCEC | 0.724 | ||||
| METAP2-Ser63 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.958 | ||||
| COAD | -0.811 | ||||
| HGSC | |||||
| ccRCC | 0.753 | ||||
| GBM | -1.801 | ||||
| HNSC | 0.367 | ||||
| LUAD | 0.972 | ||||
| LUSC | -0.06 | ||||
| non_ccRCC | -1.043 | ||||
| PDAC | |||||
| UCEC | 0.665 | ||||
| METAP2-Ser74 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | 0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | -0.707 | ||||
| METTL1-Ser128 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -0.707 | ||||
| GBM | |||||
| HNSC | 0.707 | ||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| METTL1-Ser27 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -0.842 | ||||
| GBM | |||||
| HNSC | 1.105 | ||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | -0.264 | ||||
| UCEC | |||||
| METTL13-Ser13 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | 0.707 | ||||
| LUSC | -0.707 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| METTL13-Ser181 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | 0.707 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | -0.707 | ||||
| METTL13-Ser267 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | -0.707 | ||||
| LUSC | 0.707 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| METTL14-Ser27 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | 0.707 | ||||
| LUSC | -0.707 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| METTL14-Ser54 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | 0.707 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | -0.707 | ||||
| METTL14-Thr72 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.707 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | -0.707 | ||||
| METTL16-Ser297 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | 0.707 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | -0.707 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| METTL16-Ser329 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.09 | ||||
| HGSC | 1.214 | ||||
| ccRCC | 0.062 | ||||
| GBM | 0.188 | ||||
| HNSC | -2.058 | ||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | 0.264 | ||||
| UCEC | 0.42 | ||||
| METTL16-Ser416 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 1.415 | ||||
| HGSC | |||||
| ccRCC | -0.325 | ||||
| GBM | |||||
| HNSC | -0.932 | ||||
| LUAD | -0.158 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| METTL16-Ser419 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.641 | ||||
| COAD | -0.381 | ||||
| HGSC | 0.167 | ||||
| ccRCC | 0.215 | ||||
| GBM | -1.327 | ||||
| HNSC | -0.966 | ||||
| LUAD | 1.256 | ||||
| LUSC | |||||
| non_ccRCC | 1.758 | ||||
| PDAC | |||||
| UCEC | -0.081 | ||||
| METTL16-Ser450 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | -0.707 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | 0.707 | ||||
| METTL16-Ser453 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.222 | ||||
| HGSC | -2.225 | ||||
| ccRCC | 0.528 | ||||
| GBM | 0.598 | ||||
| HNSC | 0.053 | ||||
| LUAD | 0.301 | ||||
| LUSC | 0.522 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| METTL16-Ser455 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.692 | ||||
| COAD | 0.069 | ||||
| HGSC | -2.841 | ||||
| ccRCC | 0.555 | ||||
| GBM | 0.128 | ||||
| HNSC | -0.142 | ||||
| LUAD | -0.081 | ||||
| LUSC | 0.098 | ||||
| non_ccRCC | 0.105 | ||||
| PDAC | 0.524 | ||||
| UCEC | 0.894 | ||||
| METTL16-Ser498 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | 0.707 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | -0.707 | ||||
| METTL22-Ser132 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 1.599 | ||||
| COAD | |||||
| HGSC | 1.558 | ||||
| ccRCC | -0.904 | ||||
| GBM | |||||
| HNSC | 0.031 | ||||
| LUAD | -0.035 | ||||
| LUSC | -1.091 | ||||
| non_ccRCC | -0.827 | ||||
| PDAC | 0.2 | ||||
| UCEC | -0.531 | ||||
| METTL22-Ser40 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.847 | ||||
| COAD | |||||
| HGSC | 0.214 | ||||
| ccRCC | -0.778 | ||||
| GBM | |||||
| HNSC | 1.621 | ||||
| LUAD | 0.129 | ||||
| LUSC | 0.107 | ||||
| non_ccRCC | -1.657 | ||||
| PDAC | |||||
| UCEC | -0.482 | ||||
| METTL3-Ser17 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -0.707 | ||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | 0.707 | ||||
| METTL3-Ser219 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 1.733 | ||||
| COAD | 0.141 | ||||
| HGSC | -0.789 | ||||
| ccRCC | -0.584 | ||||
| GBM | 0.319 | ||||
| HNSC | 0.611 | ||||
| LUAD | -0.14 | ||||
| LUSC | 0.202 | ||||
| non_ccRCC | -2.27 | ||||
| PDAC | 0.5 | ||||
| UCEC | 0.278 | ||||
| METTL3-Ser243 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -1.475 | ||||
| COAD | -0.326 | ||||
| HGSC | |||||
| ccRCC | 0.147 | ||||
| GBM | |||||
| HNSC | 1.385 | ||||
| LUAD | 0.461 | ||||
| LUSC | 0.784 | ||||
| non_ccRCC | -0.974 | ||||
| PDAC | |||||
| UCEC | |||||
| METTL3-Ser30 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.13 | ||||
| COAD | -0.83 | ||||
| HGSC | 1.402 | ||||
| ccRCC | -0.714 | ||||
| GBM | -0.08 | ||||
| HNSC | 2.042 | ||||
| LUAD | -1.189 | ||||
| LUSC | -0.104 | ||||
| non_ccRCC | -0.364 | ||||
| PDAC | |||||
| UCEC | -0.292 | ||||
| METTL3-Ser350 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | -1.603 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | 0.418 | ||||
| LUAD | -0.053 | ||||
| LUSC | 1.113 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | 0.125 | ||||
| METTL3-Ser43 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.531 | ||||
| COAD | -0.461 | ||||
| HGSC | 0.778 | ||||
| ccRCC | |||||
| GBM | -0.377 | ||||
| HNSC | -0.223 | ||||
| LUAD | -0.043 | ||||
| LUSC | -0.953 | ||||
| non_ccRCC | 1.531 | ||||
| PDAC | 1.626 | ||||
| UCEC | -1.346 | ||||
| METTL3-Ser50 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.65 | ||||
| HGSC | 0.502 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | -1.152 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| METTL3-Ser64 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.707 | ||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | -0.707 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| METTL3-Thr45 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.707 | ||||
| HGSC | -0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| METTL3-Thr65 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.707 | ||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | -0.707 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| METTL7A-Ser69 | |
|---|---|
| Cancer | Intensity |
| BRCA | |
| COAD | |
| HGSC | 1.47 |
| ccRCC | -0.318 |
| GBM | -0.385 |
| HNSC | |
| LUAD | -0.767 |
| LUSC | |
| non_ccRCC | |
| PDAC | |
| UCEC | |
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| Y | 1349 | U | Renal cancer/carcinoma | Phosphorylation | 16914575 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
